公开(公告)号：US12202859B2

公开(公告)日：2025-01-21

申请号：US17509808

申请日：2021-10-25

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Chao Chen ,  Michael Logan

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61P31/14 ,  C07K1/22 ,  C07K19/00 ,  C12N7/00 ,  C12N15/62 ,  C12P21/02

Abstract: The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

公开(公告)号：US11186615B2

公开(公告)日：2021-11-30

申请号：US15763370

申请日：2016-10-07

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Chao Chen ,  Michael Logan

IPC: C07K14/005 ,  C12N15/62 ,  C12P21/02 ,  C07K1/22 ,  C07K19/00 ,  A61K39/12 ,  A61P31/14 ,  A61K39/29 ,  C12N7/00 ,  A61K39/00

Abstract: The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

公开(公告)号：US20210170018A1

公开(公告)日：2021-06-10

申请号：US17122627

申请日：2020-12-15

Applicant: The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

Inventor： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC: A61K39/29 ,  C07K14/18 ,  C07K14/33 ,  C12N15/86 ,  C01F11/02 ,  C07D323/00 ,  C07K14/34 ,  A61K39/39 ,  A61P31/14 ,  A61K39/12 ,  A61P37/04 ,  C07K14/28 ,  C07K14/005 ,  A61K39/00

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20210145963A9

公开(公告)日：2021-05-20

申请号：US14783699

申请日：2014-05-15

Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

Inventor： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC: A61K39/29

Abstract: The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US10408844B2

公开(公告)日：2019-09-10

申请号：US15543943

申请日：2016-01-26

Applicant: The Governors of the University of Alberta

Inventor： Abdolamir Landi ,  David Broadhurst ,  D. Lorne J. Tyrrell ,  Michael Houghton

IPC: G01N33/68 ,  G01N33/563 ,  G01N33/58 ,  G01N33/74 ,  G01N33/96 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20

Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a subject. The methods and compositions involve measurement of at least one of proteins: IL-16, IL-7, VEGF, CXCL9, CX3CL1, CCL24, CCL19, and CCL11 in a body fluid sample of a subject suspected of having CFS/ME. Levels of one or more of the aforementioned proteins can be used to facilitate a diagnosis of a CFS/ME and/or confirm a diagnosis of CFS/ME. The methods and compositions of the present disclosure also find use in screening subjects for clinical trials and facilitating treatment decisions for a subject.

公开(公告)号：US20190224308A1

公开(公告)日：2019-07-25

申请号：US16374403

申请日：2019-04-03

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC: A61K39/29 ,  C12N15/861 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  A61K39/295 ,  A61P31/04

Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20160067332A1

公开(公告)日：2016-03-10

申请号：US14783699

申请日：2014-05-05

Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

Inventor： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC: A61K39/29

CPC classification number: A61K39/29 ,  A61K39/12 ,  A61K2039/70 ,  C12N2770/24234

Abstract: The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

Abstract translation: 本公开提供包含来自两种或更多种不同HCV基因型的HCV E1，E2或E1 / E2多肽的免疫原性组合物。 本公开提供包含来自两种或更多种不同HCV基因型的HCV E2或E1 / E2多肽的免疫原性组合物。 免疫原性组合物可用于进行诱导对HCV的免疫应答的方法。 本公开进一步提供刺激个体对HCV的免疫应答的方法。

公开(公告)号：US20240398938A1

公开(公告)日：2024-12-05

申请号：US18740380

申请日：2024-06-11

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Chao Chen ,  Darren Hockman

IPC: A61K39/29 ,  A61K39/00 ,  A61P31/14 ,  A61P37/04

Abstract: The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

公开(公告)号：US20240316186A1

公开(公告)日：2024-09-26

申请号：US18520057

申请日：2023-11-27

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC: A61K39/29 ,  A61K39/12

CPC classification number: A61K39/29 ,  A61K39/12 ,  C12N2770/24234

Abstract: The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US20240252623A1

公开(公告)日：2024-08-01

申请号：US18529858

申请日：2023-12-05

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  John L. Law ,  Abdolamir Landi

IPC: A61K39/29 ,  A61K39/00 ,  C07K14/005

CPC classification number: A61K39/29 ,  C07K14/005 ,  A61K2039/53 ,  A61K2039/70 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: The present disclosure provides nucleic acids comprising nucleotide sequences encoding hepatitis C virus (HCV) E1 and/or E2 polypeptides and/or one or more T-cell epitope polypeptides. The nucleic acids can comprise one or more modifications. The nucleic acids can be self-amplifying. The present disclosure provides compositions comprising the nucleic acids. The present disclosure provides methods of inducing an immune response to HCV in an individual, comprising administering to the individual a composition of the present disclosure.